β-Blocker effects in huntington's disease: A caution on clinical interpretation

A recent retrospective analysis of Enroll HD data suggesting β-blockers slow Huntington's disease progression has triggered patient demand but requires caution. The findings rely solely on small observational subsets and are vulnerable to bias and confounding. A prior Mendelian-randomization study found no causal link between β-blockers and HD onset; instead, genetically higher blood pressure was associated with later onset, raising concern that β-blockers' BP-lowering effects could be harmful. HD patients also have lower hypertension rates, and β-blockers carry risks such as depression and bradycardia. Given their heterogeneous mechanisms, rigorous experimental and clinical trials are needed before any clinical recommendations.